Immunotherapeutic Mechanisms of Anti-CD20 Monoclonal Antibodies

Por Taylor, Ronald P., Lindorfer, Margaret A.
Publicado em 2008

Antigenic Modulation and Rituximab Resistance

Por Taylor, Ronald P., Lindorfer, Margaret A.
Publicado em 2010

Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies

Por Taylor, Ronald P., Lindorfer, Margaret A.
Publicado em 2014

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Por Lindorfer, Margaret A., Wiestner, Adrian, Zent, Clive S., Taylor, Ronald P.
Publicado em 2012

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia

Por Lindorfer, Margaret A., Cook, Erika M., Reis, Edimara S., Ricklin, Daniel, Risitano, Antonio M., Lambris, John D., Taylor, Ronald P.
Publicado no Clin Immunol (2016)

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

Por Aue, Georg, Lindorfer, Margaret A., Beum, Paul V., Pawluczkowycz, Andrew W., Vire, Berengere, Hughes, Thomas, Taylor, Ronald P., Wiestner, Adrian
Publicado em 2010

Complement dependent cytotoxicity (CDC) in chronic lymphocytic leukemia (CLL): Ofatumumab enhances alemtuzumab CDC and reveals cells resistant to activated complement

Por Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pavey, Emily S., Nowakowski, Grzegorz S., Zent, Clive S.
Publicado no Leuk Lymphoma (2012)

A humanised antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors()

Por Paixão-Cavalcante, Danielle, Torreira, Eva, Lindorfer, Margaret A., de Cordoba, Santiago Rodriguez, Morgan, B. Paul, Taylor, Ronald P., Llorca, Oscar, Harris, Claire L.
Publicado em 2014

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Por Mo, Clifton C., Njuguna, Ndegwa, Beum, Paul V., Lindorfer, Margaret A., Vire, Berengere, Lee, Elinor, Marti, Gerald, Wilson, Wyndham H, Taylor, Ronald P., Wiestner, Adrian
Publicado em 2013

Induced Resistance to Ofatumumab Mediated Cell Clearance Mechanisms, Including Complement Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

Por Baig, Nisar A., Taylor, Ronald P., Lindorfer, Margaret A., Church, Amy K., LaPlant, Betsy R., Pettinger, Adam M., Shanafelt, Tait D., Nowakowski, Grzegorz S., Zent, Clive S.
Publicado no J Immunol (2014)

Exhaustion of cytotoxic effector systems may limit mAb-based immunotherapy in cancer patients()

Por Beurskens, Frank J., Lindorfer, Margaret A., Farooqui, Mohammed, Beum, Paul V., Engelberts, Patrick, Mackus, Wendy J.M., Parren, Paul W.H.I., Wiestner, Adrian, Taylor, Ronald P.
Publicado em 2012

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions

Por Cook, Erika M., Lindorfer, Margaret A., van der Horst, Hilma, Oostindie, Simone, Beurskens, Frank J., Schuurman, Janine, Zent, Clive S., Burack, Richard, Parren, Paul W. H. I., Taylor, Ronald P.
Publicado no J Immunol (2016)

Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor

Por Sharma, Rashmi, Zhao, Huiwu, Al-Saleem, Fetweh H., Ubaid, Ahmed Syed, Puligedda, Rama Devudu, Segan, Andrew T., Lindorfer, Margaret A., Bermudez, Rodney, Elias, Adekar, Sharad P., Simpson, Lance L., Taylor, Ronald P., Dessain, Scott K.
Publicado em 2013

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation

Por van den Bremer, Ewald TJ, Beurskens, Frank J, Voorhorst, Marleen, Engelberts, Patrick J, de Jong, Rob N, van der Boom, Burt G, Cook, Erika M, Lindorfer, Margaret A, Taylor, Ronald P, van Berkel, Patrick HC, Parren, Paul WHI
Publicado no MAbs (2015)

Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective...

Por Zent, Clive S., Taylor, Ronald P., Lindorfer, Margaret A., Beum, Paul V., LaPlant, Betsy, Wu, Wenting, Call, Timothy G., Bowen, Deborah A., Conte, Michael J., Frederick, Lori A., Link, Brian K., Blackwell, Sue E., Veeramani, Suresh, Baig, Nisar A., Viswanatha, David S., Weiner, George J., Witzig, Thomas E.
Publicado no Am J Hematol (2014)

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

Por Diebolder, Christoph A., Beurskens, Frank J., de Jong, Rob N., Koning, Roman I., Strumane, Kristin, Lindorfer, Margaret A., Voorhorst, Marleen, Ugurlar, Deniz, Rosati, Sara, Heck, Albert J. R., van de Winkel, Jan G. J., Wilson, Ian A., Koster, Abraham J., Taylor, Ronald P., Saphire, Erica Ollmann, Burton, Dennis R., Schuurman, Janine, Gros, Piet, Parren, Paul W. H. I.
Publicado no Science (2014)